Immutep's Eftilagimod Alfa Receives FDA Orphan Drug Designation for Soft Tissue Sarcoma

summarizeSummary

Immutep announced that its lead product candidate, eftilagimod alfa, received FDA Orphan Drug Designation for Soft Tissue Sarcoma, a rare cancer, based on encouraging Phase II clinical data.

check_boxKey Events

• FDA Orphan Drug Designation Granted

  The FDA granted Orphan Drug Designation (ODD) for eftilagimod alfa (efti) for the treatment of Soft Tissue Sarcoma (STS), a rare cancer.

• Benefits of ODD

  ODD provides regulatory support, potential tax credits, fee exemptions, and seven years of market exclusivity upon approval, encouraging development for rare diseases.

• Supported by Positive Phase II Data

  The designation is based on encouraging clinical data from the investigator-initiated Phase II EFTISARC-NEO trial, which met its primary endpoint in 38 evaluable patients with resectable STS.

• Strategic Path Forward

  This designation offers a potential direct step forward into a late-stage study in the neoadjuvant setting for STS, providing a new strategic direction for efti, especially after the discontinuation of the TACTI-004 trial.

auto_awesomeAnalysis

This FDA Orphan Drug Designation is a significant positive development for Immutep, providing regulatory support, potential tax credits, fee exemptions, and seven years of market exclusivity upon approval for eftilagimod alfa in Soft Tissue Sarcoma. The designation is supported by promising Phase II data from the EFTISARC-NEO trial, which met its primary endpoint and showed immune activation. This milestone offers a clear path towards a late-stage study, which is particularly important following the discontinuation of the Phase III TACTI-004 trial, providing a new strategic direction for the company's lead candidate. This formal SEC filing follows a press release issued earlier today announcing the same designation.